학술논문
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Document Type
Article
Author
Mai, Elias K; Goldschmidt, Hartmut; Miah, Kaya; Bertsch, Uta; Besemer, Britta; Hänel, Mathias; Krzykalla, Julia; Fenk, Roland; Schlenzka, Jana; Munder, Markus; Dürig, Jan; Blau, Igor W; Huhn, Stefanie; Hose, Dirk; Jauch, Anna; Kunz, Christina; Mann, Christoph; Weinhold, Niels; Scheid, Christof; Schroers, Roland; von Metzler, Ivana; Schieferdecker, Aneta; Thomalla, Jörg; Reimer, Peter; Mahlberg, Rolf; Graeven, Ullrich; Kremers, Stephan; Martens, Uwe M; Kunz, Christian; Hensel, Manfred; Benner, Axel; Seidel-Glätzer, Andrea; Weisel, Katja C; Raab, Marc S; Salwender, Hans J; Adrian, Nicole; Bernhard, Helga; Böck, Hans-Peter; Bolling, Claus; Dingeldein, Gerrit; Emde, Till-Oliver; Ferstl, Barbara; Fietz, Thomas; Fronhoffs, Stefan; Fuhrmann, Stephan; Fuxius, Stefan; Geer, Thomas; Görner, Martin; Guenther, Barbara; Hartmann, Frank; Heilmeier, Bernhard; Heinsch, Michael; Hoffmann, Martin; Holderried, Tobias A.W.; Klein, Stefan; Klump, Martin; Knauf, Wolfgang; La Rosée, Paul; Lange, Elisabeth; Lindemann, Walter; Lopez, Roderico; Mayer, Frank; Nückel, Holger; Papesch, Eva; Procaccianti, Maria; Reichart, Alexander; Rummel, Mathias; Scheuer, Lars; Schmitt, Hans-Roland; Staib, Peter; Steiniger, Heike; Tischler, Hans-Joachim; Ulshöfer, Thomas; Verbeek, Walter; Wacker, Alexander; Zirpel, Iris
Source
The Lancet Haematology; February 2024, Vol. 11 Issue: 2 pe101-e113, 13p
Subject
Language
ISSN
23523026
Abstract
The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible patients with newly diagnosed multiple myeloma.